CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd

CSL Limited and Novo Nordisk Pharmaceuticals Pty Ltd were involved in a dispute regarding a patent before the Federal Court of Australia. The core issue revolved around the discovery of certain documents that CSL was asked to produce for inspection by Novo Nordisk. The dispute centred on the discoverability of these documents under specific provisions of the Federal Court Rules, specifically in relation to the applicants' appreciation of the need to amend the patent, their reasons for making such an application, and matters discussed during a particular meeting.

The court had to determine whether CSL was required to disclose certain documents to Novo Nordisk. The legal issues included whether the documents were discoverable under O 15 r 2(3) of the Federal Court Rules and whether any claim of privilege could prevent their disclosure. The court also needed to assess the relevance of these documents to the patent amendment process and the meeting held on 2 June 2009.

The court found that CSL must produce for inspection specific documents, excluding any that were subject to a claim of privilege. These documents needed to be discoverable under the relevant rule and had to pertain to the timing, existence, or content of CSL's appreciation of the need to amend the patent, the reasons for the amendment application, or the discussions held in the specified meeting. The court concluded that the respondents' motion, other than the specific document inspection order, should be refused, and reserved the costs.